<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862377</url>
  </required_header>
  <id_info>
    <org_study_id>BuS2020</org_study_id>
    <nct_id>NCT04862377</nct_id>
  </id_info>
  <brief_title>Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia.</brief_title>
  <acronym>BuS</acronym>
  <official_title>Efficacy and Safety of the Intratracheal Administration of Budesonide With Porcine Pulmonary Surfactant in Very Preterm Infants to Prevent Bronchopulmonary Dysplasia: Randomized Clinical Trial (BuS Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine whether intratracheal administration of budesonide&#xD;
      combined with surfactant, as compared to surfactant alone, will modify ecographic (lung&#xD;
      ultrasound score) and biological markers (IL-6 concentration in respiratory secretions) at 7&#xD;
      days of life in preterm infants ≤32 weeks of gestational age (GA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchopulmonary dysplasia (BPD) is one of the main morbidities associated with extreme&#xD;
      prematurity and, despite the improvement of respiratory care in the latest years, overall&#xD;
      incidence is not decreasing. Etiology of BPD is multifactorial and local inflammation plays&#xD;
      an important role in it, therfore, local anti-inflammatory drugs could be effective in&#xD;
      preventing BPD.&#xD;
&#xD;
      Recent randomised trials have shown a lower incidence of BPD/death with the use of a&#xD;
      combination of budesonide with surfactat compared to surfactant alone, and further clinical&#xD;
      trials are currently ongoing.&#xD;
&#xD;
      This is a controlled phase IV, randomised, unicenter clinical trial designed to evaluate the&#xD;
      effect of intratracheal administration of budesonide combined with surfactant, as compared to&#xD;
      surfactant alone, in BPD in preterm infants ≤32 weeks of GA. Investigators will compare&#xD;
      ecographic and biological markers, as well as respiratory outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomised trial. Infants who fit criteria for surfactante administration will be randomly assigned into 2 groups: &quot;Standard treatment group&quot; receiving only intratracheal surfactant, and &quot;Interventional treatment group&quot; receiving intratracheal surfactant combined with budesoinde.&#xD;
It will be a third group of patients ≤32 weeks (&quot;Control group&quot;) who won´t fit criteria for surfactant administration.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>When eligibility of an infant is confirmed, consent will be obtained. Infants candidates to surfactant administration will be randomly assigned to either receive surfactant with budesonide, or surfactant alone, using a web-based randomisation system with an allocation ratio of 1:1.&#xD;
Primary care provider in charge of the patient at the time of the enrolment will be responsible for the randomization, and for the preparation of the drug (surfactant alone, or surfactant with budesonide).&#xD;
Participants will be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Lung ultrasound score at 7 days of life.</measure>
    <time_frame>7 days of life</time_frame>
    <description>LUS will be performed with the patients in supine position and slightly lying on the side of the taken view. Each lung will be divided in five areas through longitudinal orientation and images will be taken using the linear probe (VF 13-5MHz).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-6 concentration in respiratory secretions at 7 days of life.</measure>
    <time_frame>7 days of life</time_frame>
    <description>Nasopharyngeal aspirate (NPA) will be collected by standard procedure. IL-6 concentration will be determined by Human IL-6 Quantikine ELISA (R&amp;D Systems Inc., Minneapolis, MN, USA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung ultrasound score at 28 days of life.</measure>
    <time_frame>28 days of life</time_frame>
    <description>LUS will be performed with the patients in supine position and slightly lying on the side of the taken view. Each lung will be divided in five areas through longitudinal orientation and images will be taken using the linear probe (VF 13-5MHz).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 concentration in respiratory secretions at 28 days of life.</measure>
    <time_frame>28 days of life</time_frame>
    <description>Nasopharyngeal aspirate (NPA) will be collected by standard procedure. IL-6 concentration will be determined by Human IL-6 Quantikine ELISA (R&amp;D Systems Inc., Minneapolis, MN, USA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of oxygen</measure>
    <time_frame>7 and 28 days of age, 36 weeks of post-menstrual age.</time_frame>
    <description>Number of days on FiO2 &gt;21% supplied by any respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of respiratory support</measure>
    <time_frame>7 and 28 days of age, 36 weeks of post-menstrual age.</time_frame>
    <description>Number of days on each level of respiratory support:&#xD;
No respiratory support&#xD;
Nasal cannula at flow rates ≤ 2L/min&#xD;
Nasal cannula at flow rates &gt; 2L/min&#xD;
CPAP/BIPAP&#xD;
Invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean airway pressure (MAP)</measure>
    <time_frame>7 and 28 days of age, 36 weeks of post-menstrual age.</time_frame>
    <description>Maximum MAP mesured in cmH2O at 7 and 28 days of age, 36 weeks of postmenstrual age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bronchopulmonary dysplasia</measure>
    <time_frame>36 weeks of post-menstrual age.</time_frame>
    <description>BPD will be defined according to the 2001 workshop definition (Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine. American Lung Association; 2001; pp 1723-9).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory status and neurodevelopment</measure>
    <time_frame>24 months of age.</time_frame>
    <description>Neurodevelopment will be assessed using Bayley-III test.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <condition>Respiratory Distress Syndrome in Premature Infant</condition>
  <condition>Prematurity</condition>
  <arm_group>
    <arm_group_label>Standard treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants randomised to the &quot;standard treatment&quot; arm will receive intratracheal surfactant as per usual clinical indications of respiratory distress syndrome in these preterm infants.&#xD;
In that sense, and based in those clinical indications, we have developed a risk calculator for surfactant administration in preterm infants ≤32 weeks GA. We will use it to decide what patients will receive surfactant (calculator available on: https://1drv.ms/x/s!Arjkl83HIXSngP8TWh8O6oi6Ztdw3w?e=gNCMxP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants randomised to the &quot;interventional treatment&quot; arm will receive intratracheal surfactant mixed with budesonide. Indication of surfactant, as equal as for the &quot;standard treatment&quot; arm, will be decided using the calculator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Infants ≤32 weeks with no indications for surfactant administration. Their clinical management will be the usual in our neonatal unit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poractant Alfa Intratracheal Suspension [Curosurf]</intervention_name>
    <description>Poractant alfa (Curosurf®):&#xD;
First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg.</description>
    <arm_group_label>Interventional treatment group</arm_group_label>
    <arm_group_label>Standard treatment group</arm_group_label>
    <other_name>Curosurf®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 0.5 MG/ML</intervention_name>
    <description>Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):&#xD;
First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide.</description>
    <arm_group_label>Interventional treatment group</arm_group_label>
    <other_name>Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants born equal or earlier than 32 weeks of gestational age admitted in the&#xD;
             Neonatal Intensive Care Unit.&#xD;
&#xD;
          -  Parental consent signed.&#xD;
&#xD;
          -  Less than or equal to 48 hours postnatal age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infants with known major congenital anomalies (eg. congenital upper airwayobstruction,&#xD;
             congenital lung anomaly, severe pulmonary hypoplasia, hydrops,neuromuscular diseases,&#xD;
             chromosomopaties)&#xD;
&#xD;
          -  Infants with poor prognosis and risk of imminent death&#xD;
&#xD;
          -  Infants who have received the first dose of surfactant before of the enrolment to the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>48 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Teresa-Palacio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta Teresa-Palacio, MD</last_name>
    <phone>0034 93 227 56 00</phone>
    <phone_ext>7503</phone_ext>
    <email>teresa@clinic.cat</email>
  </overall_contact>
  <link>
    <url>https://1drv.ms/x/s!Arjkl83HIXSngP8TWh8O6oi6Ztdw3w?e=gNCMxP</url>
    <description>Risk calculator for surfactant administration</description>
  </link>
  <reference>
    <citation>Heo M, Jeon GW. Intratracheal administration of budesonide with surfactant in very low birth weight infants to prevent bronchopulmonary dysplasia. Turk J Pediatr. 2020;62(4):551-559. doi: 10.24953/turkjped.2020.04.004.</citation>
    <PMID>32779407</PMID>
  </reference>
  <reference>
    <citation>Oulego-Erroz I, Alonso-Quintela P, Terroba-Seara S, Jiménez-González A, Rodríguez-Blanco S. Early assessment of lung aeration using an ultrasound score as a biomarker of developing bronchopulmonary dysplasia: a prospective observational study. J Perinatol. 2021 Jan;41(1):62-68. doi: 10.1038/s41372-020-0724-z. Epub 2020 Jul 14.</citation>
    <PMID>32665687</PMID>
  </reference>
  <reference>
    <citation>Alonso-Ojembarrena A, Lubián-López SP. Lung ultrasound score as early predictor of bronchopulmonary dysplasia in very low birth weight infants. Pediatr Pulmonol. 2019 Sep;54(9):1404-1409. doi: 10.1002/ppul.24410. Epub 2019 Jun 10.</citation>
    <PMID>31216121</PMID>
  </reference>
  <reference>
    <citation>Förster K, Sass S, Ehrhardt H, Mous DS, Rottier RJ, Oak P, Schulze A, Flemmer AW, Gronbach J, Hübener C, Desai T, Eickelberg O, Theis FJ, Hilgendorff A. Early Identification of Bronchopulmonary Dysplasia Using Novel Biomarkers by Proteomic Screening. Am J Respir Crit Care Med. 2018 Apr 15;197(8):1076-1080. doi: 10.1164/rccm.201706-1218LE.</citation>
    <PMID>29053024</PMID>
  </reference>
  <reference>
    <citation>Venkataraman R, Kamaluddeen M, Hasan SU, Robertson HL, Lodha A. Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis. Pediatr Pulmonol. 2017 Jul;52(7):968-975. doi: 10.1002/ppul.23680. Epub 2017 Feb 6. Review.</citation>
    <PMID>28165675</PMID>
  </reference>
  <reference>
    <citation>Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, Tsai CH, Lin HC. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2016 Jan 1;193(1):86-95. doi: 10.1164/rccm.201505-0861OC.</citation>
    <PMID>26351971</PMID>
  </reference>
  <reference>
    <citation>Kuo HT, Lin HC, Tsai CH, Chouc IC, Yeh TF. A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants. J Pediatr. 2010 Apr;156(4):537-41. doi: 10.1016/j.jpeds.2009.10.049. Epub 2010 Feb 6.</citation>
    <PMID>20138301</PMID>
  </reference>
  <reference>
    <citation>Yeh TF, Lin HC, Chang CH, Wu TS, Su BH, Li TC, Pyati S, Tsai CH. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics. 2008 May;121(5):e1310-8. doi: 10.1542/peds.2007-1973. Epub 2008 Apr 21.</citation>
    <PMID>18426851</PMID>
  </reference>
  <reference>
    <citation>Aldecoa-Bilbao V, Balcells-Esponera C, Herranz Barbero A, Borràs-Novell C, Izquierdo Renau M, Iriondo Sanz M, Salvia Roigés M. Lung ultrasound for early surfactant treatment: Development and validation of a predictive model. Pediatr Pulmonol. 2021 Feb;56(2):433-441. doi: 10.1002/ppul.25216. Epub 2020 Dec 23.</citation>
    <PMID>33369257</PMID>
  </reference>
  <reference>
    <citation>Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001 Jun;163(7):1723-9.</citation>
    <PMID>11401896</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchopulmonary dysplasia</keyword>
  <keyword>Respiratory Distress Syndrome in premature infant</keyword>
  <keyword>Prematurity</keyword>
  <keyword>Lung injury</keyword>
  <keyword>Poractant alfa</keyword>
  <keyword>Pulmonary surfactant</keyword>
  <keyword>Budesonide</keyword>
  <keyword>Anti-inflammatory agents</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Lung ultrasound</keyword>
  <keyword>IL-6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Poractant alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

